問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Chi Mei Hospital, Liouying

Division of Hematology & Oncology

List

200Cases

2023-02-01 - 2026-12-31

Phase III

Active
ROSY-T: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment

  • Condition/Disease

    Cancer

  • Test Drug

    TAGRISSO (泰格莎膜衣錠)

Participate Sites
6Sites

Recruiting6Sites

2023-07-01 - 2027-11-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting8Sites

Recruiting2Sites

2015-02-19 - 2019-06-25

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated5Sites

Suspended1Sites

2018-07-03 - 2020-08-31

Phase III

Completed
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    BGB-A317

Participate Sites
8Sites

Terminated7Sites

林振源
China Medical University Hospital-Taipei

未分科

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2019-06-01 - 2024-09-30

Phase III

Completed
A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy and safety of tislelizumab (BGB-A317) in combination with chemotherapy as first-line treatment in patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma

  • Condition/Disease

    unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma

  • Test Drug

    BGB-A317

Participate Sites
5Sites

Recruiting1Sites

Terminated4Sites

林振源
China Medical University Hospital

Division of Hematology & Oncology

2025-02-28 - 2032-06-30

Phase III

Active
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

  • Condition/Disease

    Early breast cancer that is lymph node–positive, estrogen receptor–positive, and human epidermal growth factor receptor 2 (HER2)–negative, with a high risk of recurrence.

  • Test Drug

    Elacestrant

Participate Sites
13Sites

Recruiting13Sites

2024-11-27 - 2028-05-29

Phase III

Active
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    tablet

Participate Sites
10Sites

Recruiting10Sites

2026-06-01 - 2030-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting9Sites

2021-09-27 - 2028-02-15

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-01-31 - 2032-12-03

Phase III

Active
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence

  • Condition/Disease

    Breast Neoplasms

  • Test Drug

    Imlunestrant (LY3484356)ExemestaneTamoxifenAnastrozoleLetrozole

Participate Sites
11Sites

Recruiting11Sites

1 7 8 9 10 11 20
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB